188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I–II study
Mark Ringhoffer, Norbert Blumstein, Bernd Neumaier, Gerhard Glatting, Stephanie von Harsdorf, Inga Buchmann, Markus Wiesneth, Jörg Kotzerke, Thorsten Zenz, Andreas K. Buck, Peter Schauwecker, StephanVolume:
130
Année:
2005
Langue:
english
Pages:
10
DOI:
10.1111/j.1365-2141.2005.05663.x
Fichier:
PDF, 171 KB
english, 2005